about
UDP-glucuronosyltransferase activity, expression and cellular localization in human placenta at termMetabolic interactions with piperazine-based 'party pill' drugsEffects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomesPharmacokinetic Properties of Adenosine Amine Congener in Cochlear Perilymph after Systemic AdministrationAdenosine amine congener as a cochlear rescue agent.Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients.The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation.Varenicline improves motor and cognitive symptoms in early Huntington's disease.Indirect regulation of CYP2C19 gene expression via DNA methylation.Human placental glucuronidation and transport of 3'azido-3'-deoxythymidine and uridine diphosphate glucuronic acid.3'-azido-3'-deoxythymidine (AZT) induces apoptosis and alters metabolic enzyme activity in human placenta.In vivo metabolism of norbormide in rats and mice.In vitro metabolism of norbormide in rat, mouse and guinea pig liver preparations.Validation of an LC-MS method for the detection and quantification of BZP and TFMPP and their hydroxylated metabolites in human plasma and its application to the pharmacokinetic study of TFMPP in humans.Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species.In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac.A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide.Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans.Synthesis and methemoglobinemia-inducing properties of analogues of para-aminopropiophenone designed as humane rodenticides.Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo.Gonadal influence on the metabolism and haematological toxicity of dapsone in the rat.Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans.Metabolism of praziquantel in kingfish Seriola lalandi.Aerobic 2- and 4-nitroreduction of CB 1954 by human liver.Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro.Influence of mustard group structure on pathways of in vitro metabolism of anticancer N-(2-hydroxyethyl)-3,5-dinitrobenzamide 2-mustard prodrugs.Synthesis and methemoglobinemia-inducing properties of benzocaine isosteres designed as humane rodenticides.The effect of 2,2'-substitution on the metabolism and toxicity of dapsone in vitro and in vivo.Pharmacokinetics and in vivo chemosuppressive activity studies on cryptolepine hydrochloride and cryptolepine hydrochloride-loaded gelatine nanoformulation designed for parenteral administration for the treatment of malaria.Antimutagenic effects of wheat bran diet through modification of xenobiotic metabolising enzymes.Specific determination of intact cisplatin and monohydrated cisplatin in human plasma and culture medium ultrafiltrates using HPLC on-line with inductively coupled plasma mass spectrometry.Glucuronidation of anticancer prodrug PR-104A: species differences, identification of human UDP-glucuronosyltransferases, and implications for therapy.Regulating new psychoactive drugs: innovation leading to compromise.A systematic review of clozapine-induced myocarditis.Bioactivation and inactivation of aflatoxin B1 by human, mouse and rat liver preparations: effect on SCE in human mononuclear leucocytes.An investigation of the formation of cytotoxic, genotoxic, protein-reactive and stable metabolites from naphthalene by human liver microsomesPharmacokinetics of cytisine, an α4β2nicotinic receptor partial agonist, in healthy smokers following a single doseAscending single dose pharmacokinetics of cytisine in healthy adult smokersWhich CYP2B6 Variants Have Functional Consequences for Cyclophosphamide Bioactivation?
P50
Q28202360-C618A3BE-D0FD-46EB-9119-C2AC97CC737AQ28251405-B62B586E-F63C-44F0-8656-F054EFB0D9FBQ28345530-9BD1153B-6146-4789-B465-6E7BE4B03EF3Q30363358-BECC9489-48EE-427B-BCB0-583F3A5B0CC1Q30430524-3681E213-C717-4616-A822-CC55049BBFF8Q34346713-C730149F-7131-4EB6-BCF6-7A421679F3E1Q34457423-02E7076D-BEC4-4791-AE40-8156D1763231Q37279618-58F45F21-A09D-4F11-924C-8C064E694B06Q38608601-EFF69FEC-FC07-49C4-9676-A798ED6E5FFBQ40534505-7C3E921D-6412-44D6-9CFC-F4EB0942AE15Q40627465-4A9209D4-2EDB-4392-803C-73D17A40385EQ42729318-E7D183AC-BB20-4ED5-AA17-11942E6FEA4DQ42729394-CE705AC0-E0C3-4F87-B772-2F33D445E2A0Q43038051-BBF97E79-D956-4F6C-8B4A-670110F17725Q43599993-94A3A049-F699-42F6-A687-229C8830897BQ43602586-A61EE7EA-3004-430E-BF8C-471D05BE5143Q43679472-31256F8C-0656-4A82-A8DD-5FE7A4EB0AEEQ43699660-D5A8F36E-709F-4539-A92B-CAEB00843FA2Q43877930-57000EE8-1E74-4C5E-BB7F-4CF2B54F8860Q43893963-C9F6CC1E-CD90-443E-ACEB-5825E7BF5A77Q43898845-99C44430-AB76-4078-B5C3-F020DCD6F5DFQ44531314-47A23A40-6CAB-4E82-B7EA-3ECCA7693E7FQ44838350-44FEA0D7-F7DD-411F-9CD1-E353D0A41FC9Q46671169-C958C2EA-833B-42AC-A876-96EE88ECE26FQ46675687-F54B1EAB-C0F0-4F36-8B34-E067E0DE442CQ46711988-90AACDCA-88C2-4098-B02D-CA7CAD9D03B6Q46903212-C2EF1207-8FAB-4CB8-8EDF-6DE295FBFA18Q47902737-0C64D9BF-18A7-436E-A382-B2D38A52B117Q47986355-AAEA1915-3313-47DB-A646-5576A8D75489Q48036870-8B01A457-82E3-43C4-AC73-BF0BE8976955Q50118876-0D5169E9-23CB-4FBF-8964-873068BABF87Q51203395-1B3FB036-0A3E-4662-B227-570BB25D56AEQ51587907-30E3D96F-6D33-4CC6-A6CE-9CA3238FE355Q51801769-39E354A1-C626-4CD0-96CA-9B541EDFF007Q52630774-34B9BBC2-3559-49AD-AA04-5B4AFDB4A290Q53446036-D843366B-D800-47C3-AB8F-0B3251808564Q57302844-A9C742CA-D63D-4C42-AE3A-87FBD6879017Q57479449-9A77856D-6381-4032-949B-7732A76B6513Q62232127-F4F42B9B-D906-41D4-9566-76EDDC4DA812Q62232151-9BB771B5-204B-4DC1-8EA5-32B544AF942B
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Malcolm D Tingle
@es
Malcolm D. Tingle
@en
Malcolm D. Tingle
@nl
Malcolm D. Tingle
@sl
type
label
Malcolm D Tingle
@es
Malcolm D. Tingle
@en
Malcolm D. Tingle
@nl
Malcolm D. Tingle
@sl
prefLabel
Malcolm D Tingle
@es
Malcolm D. Tingle
@en
Malcolm D. Tingle
@nl
Malcolm D. Tingle
@sl
P106
P1153
7003928292
P21
P31
P496
0000-0002-4443-7963
P569
2000-01-01T00:00:00Z